Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.

PURPOSE We aimed to identify signaling pathways involved in the response and resistance to aromatase inhibitor therapy in patients with breast cancer. PATIENTS AND METHODS One hundred fourteen women with T2-4 N0-1, estrogen receptor (ER) alpha-positive tumors were randomly assigned to neoadjuvant letrozole or letrozole plus metronomic cyclophosphamide. Twenty-four tumor proteins involved in apoptosis, cell survival, hypoxia, angiogenesis, growth factor, and hormone signaling were assessed by immunohistochemistry in pretreatment samples (eg, caspase 3, phospho- mammalian target of rapamycin, hypoxia-inducible factor 1alpha [HIF-1alpha], vascular endothelial growth factor, mitogen-activated protein kinase [MAPK], phosphorylated epidermal growth factor receptor, phosphorylated ERalpha [pERalpha]). A multivariate generalized linear regression approach was applied using a penalized least-square minimization to perform variable selection and regularization. Ten-fold cross-validation and iterative leave-one-out were employed to validate and test the model, respectively. Tumor size, nodal status, age, tumor grade, histological type, and treatment were included in the analysis. RESULTS Ninety-one patients (81%) attained a disease response, 48 achieved a complete clinical response (43%) whereas 22 did not respond (19%). Increased pERalpha and decreased p44/42 MAPK were significant factors for complete response to treatment in all leave-one-out iterations. Increased p44/42 MAPK and HIF-1alpha were significant factors for treatment resistance in all leave-one-out iterations. There was no significant interaction between these variables and treatment. CONCLUSION Activated ERalpha form was an independent factor for sensitivity to chemoendocrine treatment, whereas HIF-1alpha and p44/42 MAPK were independent factors for resistance. Although further confirmatory analyses are needed, these findings have clear potential implications for future strategies in the management of clinical trials with aromatase inhibitors in the breast cancer.

[1]  S. Fox,et al.  Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer , 2007, Breast Cancer Research.

[2]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Fox,et al.  Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. , 2006, Endocrine-related cancer.

[4]  Manuela Milani,et al.  Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer , 2006, Clinical Cancer Research.

[5]  S. Fox,et al.  Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Mouret-Reynier,et al.  Neoadjuvant endocrine therapy in breast cancer. , 2006, Breast.

[7]  H. Stein,et al.  Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. , 2006, European journal of immunology.

[8]  Manuela Milani,et al.  Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  R. Schiff,et al.  Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators , 2005, Cancer Chemotherapy and Pharmacology.

[10]  I. Hedenfalk,et al.  ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERα: a combination therapy potentially targeting hypoxic and dormant tumor cells , 2005, Oncogene.

[11]  L. Carey,et al.  American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. , 2005, Journal of the National Cancer Institute.

[12]  M. Dowsett,et al.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Nicholson,et al.  Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. , 2005, Endocrine-related cancer.

[14]  I. Ellis,et al.  Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. , 2005, Endocrine-related cancer.

[15]  Gauri Sabnis,et al.  Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. , 2005, Cancer research.

[16]  Fiona Powrie,et al.  Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single‐cell level , 2005, European journal of immunology.

[17]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[18]  S. Verma,et al.  Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? , 2005, Cancer treatment reviews.

[19]  R. Schiff,et al.  Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. , 2005, Clinical Cancer Research.

[20]  M. Dowsett,et al.  Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  R. Fisher,et al.  Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Manuel Hidalgo,et al.  Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.

[23]  A. Harris,et al.  Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.

[24]  L. Murphy,et al.  Phospho-Serine-118 Estrogen Receptor-α Expression Is Associated with Better Disease Outcome in Women Treated with Tamoxifen , 2004, Clinical Cancer Research.

[25]  S. Ziegler,et al.  Cutting Edge: Estrogen Drives Expansion of the CD4+CD25+ Regulatory T Cell Compartment1 , 2004, The Journal of Immunology.

[26]  C. Sweep,et al.  Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients. , 2004, International journal of oncology.

[27]  S. Fox,et al.  Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor α and Improved Survival in Primary Human Breast Carcinomas , 2004, Clinical Cancer Research.

[28]  L. Murphy,et al.  Phospho-Serine-118 Estrogen Receptor-α Detection in Human Breast Tumors in Vivo , 2004, Clinical Cancer Research.

[29]  R. Nicholson,et al.  Nonendocrine Pathways and Endocrine Resistance , 2004, Clinical Cancer Research.

[30]  L. Murphy,et al.  Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  C. Osborne,et al.  Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.

[32]  C. Osborne,et al.  Mechanisms of tamoxifen resistance , 2004, Breast Cancer Research and Treatment.

[33]  A. Brodie,et al.  Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. , 2003, Cancer research.

[34]  A. Barqawi,et al.  Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma , 2003, Cancer.

[35]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[36]  H. Iwata,et al.  Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer , 2003, Cancer Chemotherapy and Pharmacology.

[37]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[38]  M. Dowsett,et al.  Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.

[39]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[40]  G. Semenzato.  TARGETING HIF-1 FOR CANCER THERAPY , 2003 .

[41]  H. Iwata,et al.  Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. , 2003, Cancer chemotherapy and pharmacology.

[42]  H. Kurokawa,et al.  ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  D. Coradini,et al.  Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens , 2003, Cellular and Molecular Life Sciences CMLS.

[44]  M. Dowsett,et al.  Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[45]  A. Brodie,et al.  The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  H. Nagasawa,et al.  Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives. , 2002, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[47]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[48]  J. Slingerland,et al.  Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[49]  M. Ellis,et al.  Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  J. Kurebayashi,et al.  Hypoxia Reduces Hormone Responsiveness of Human Breast Cancer Cells , 2001, Japanese journal of cancer research : Gann.

[51]  A. Harris,et al.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[53]  A. Lenferink,et al.  Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.

[54]  M. Brizzi,et al.  p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  D. Mottet,et al.  ERK activation upon hypoxia: involvement in HIF‐1 activation , 2000, FEBS letters.

[56]  J. Pouysségur,et al.  p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1* , 1999, The Journal of Biological Chemistry.

[57]  J. Robertson,et al.  Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.